<DOC>
	<DOCNO>NCT00253370</DOCNO>
	<brief_summary>This phase II trial study well give sorafenib together docetaxel cisplatin work treat patient metastatic locally advanced gastric gastroesophageal junction cancer remove surgery . Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , docetaxel cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving sorafenib together docetaxel cisplatin may kill tumor cell .</brief_summary>
	<brief_title>Sorafenib , Docetaxel , Cisplatin Treating Patients With Metastatic Advanced Gastric Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate response rate ( complete response partial response ) combination BAY 43-9006 docetaxel cisplatin oxaliplatin patient gastric GEJ adenocarcinoma . II . To evaluate progression-free survival ( PFS ) overall survival . III . To evaluate toxicity BAY 43-9006 patient advance metastatic gastric GEJ adenocarcinoma combine docetaxel/cisplatin docetaxel/oxaliplatin . IV . To evaluate Raf status tumor correlate response PFS presence absence activate mutation B-Raf . V. To analyze pharmacokinetic pharmacogenetic property BAY 43-9006 include angiogenesis , monooxygenases , polymorphisms multidrug-resistance ( MDR ) . This study conduct via E1Y03 mechanism . OUTLINE : This open-label , multicenter study . Patients stratify accord Siewert 's tumor location ( I vs II v III ) extent disease ( locally advance unresectable v distant metastasis ) . Patients receive oral BAY 43-9006 twice daily day 1-21 . Patients also receive docetaxel intravenously ( IV ) 1 hour cisplatin IV 1-2 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 3 year . An addition arm contain oxaliplatin propose meet accrual goal move forward study close accrual July , 2007 final accrual 44 patient .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must measurable , histologically confirm , advance unresectable metastatic gastric GEJ adenocarcinoma ; image study must conduct within 4 week study entry For patient GEJ adenocarcinoma , tumor location specify use Siewert classification use NCIsponsored Phase II study disease sit Patients must ECOG performance status 01 Patients may adjuvant chemotherapy chemoradiation therapy , without 5Fluorouracil treatment perform 6 month evidence recurrent metastatic disease Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Must follow baseline laboratory value obtain within 2 week registration : Absolute Granulocyte Count &gt; = 1,500/mm^3 Platelet Count &gt; = 100,000/mm^3 White Blood Count &gt; = 3,000/mm^3 Serum Creatinine &lt; = 1.5 mg/dl Total Bilirubin &lt; = 2.0 mg/dl Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) /alkaline phosphatase ( Alk phos ) &lt; = 2.5 x upper limit normal Patients must able take oral medication without crush , dissolve chew tablet Prior radiotherapy , chemotherapy investigational therapy , particularly inhibitor tyrosine Kinases , signal transduction angiogenesis treatment recurrent and/or metastatic gastric GEJ adenocarcinoma Receiving investigational agent Being pregnant breastfeeding ; female childbearing potential must blood urine test within 2 week prior registration rule pregnancy HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction BAY 439006 Brain metastasis History allergic reaction attribute compound similar chemical biologic composition BAY 439006 Acute active infection significant clinical intervention per physician 's discretion Previous concurrent malignancy allow , except : Nonmelanoma skin cancer situ cervical cancer Treated cancer patient continuously diseasefree five year Other uncontrolled intercurrent illness include , limited : uncontrolled hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia psychiatric illness/addictive disorder would limit compliance study requirement Evidence bleed diathesis Concurrent cytochrome P450 enzymeinducing antiepileptic drug : Phenytoin Carbamazepine Phenobarbital Rifampin St. John 's Wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>gastroesophageal junction adenocarcinoma</keyword>
</DOC>